Skip to main content
SpringerLink
Log in

Is a Large-Scale Screening for Alzheimer’s Disease Possible? Yes, in a Few Years

  • Commentary
  • Published:
The Journal of Prevention of Alzheimer's Disease Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, et al. Plasma Biomarkers of AD Emerging As Essential Tools For Drug Development: An EU/US CTAD Task Force Report. J Prev Alz Dis 2019;6(3):169–173

    CAS  Google Scholar 

  2. McKhann G, Knopman DS, Chertkow H, Hymann B, Jack CR, Kawas C, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

    Article  Google Scholar 

  3. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Vol. 7, Alzheimer’s and Dementia. 2011. p. 270–9.

    Article  Google Scholar 

  4. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Vol. 13, The Lancet Neurology. 2014. p. 614–29.

    Article  Google Scholar 

  5. Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, et al. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol. 2018

  6. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid-ß biomarkers for Alzheimer’s disease. Nature. 2018

    Google Scholar 

  7. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019;1–9.

    Google Scholar 

  8. Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, et al. The EMIF-AD Multimodal Biomarker Discovery study: Design, methods and cohort characteristics. Alzheimer’s Res Ther. 2018

  9. Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland

    F. Ribaldi, Daniele Altomare & G. B. Frisoni

  2. Laboratory of Alzheimer’s Neuroimaging and Alzheimer’s Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

    F. Ribaldi

  3. University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy

    F. Ribaldi

  4. Memory Clinic, University Hospital of Geneva, Geneva, Switzerland

    Daniele Altomare & G. B. Frisoni

Authors
  1. F. Ribaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniele Altomare
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. B. Frisoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniele Altomare.

Ethics declarations

Conflict of interest: Dr. Ribaldi and Dr. Altomare have nothing to disclose. Dr. Frisoni reports grants from Alzheimer Forum Suisse, grants from Académie Suisse des Sciences Médicales (ASSM), grants from Avid Radiopharmaceuticals, grants from Biogen, grants from GE International, grants from Guerbert, grants from IFRAD Suisse (Association Suisse pour la Recherche sur l’Alzheimer), grants from Ixico, grants from Merz, grants from Nestlé, grants from Novartis, grants from Piramal, grants from Roche, grants from Siemens, grants from Teva Pharma, grants from Vifor Pharma, grants from Alzheimer’s Association, personal fees from AstraZeneca, personal fees from Avid Radiopharmaceuticals, personal fees from Elan, personal fees from GE International, personal fees from Lundbeck, personal fees from Pfizer, personal fees from Taurx, outside the submitted work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ribaldi, F., Altomare, D. & Frisoni, G.B. Is a Large-Scale Screening for Alzheimer’s Disease Possible? Yes, in a Few Years. J Prev Alzheimers Dis 6, 221–222 (2019). https://doi.org/10.14283/jpad.2019.29

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.14283/jpad.2019.29

Search

Navigation